Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents

Article Immunology

Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children

Samantha M. Olson et al.

Summary: During the 2019-2020 flu season, vaccination reduced the risk of critical and life-threatening influenza in children, despite the mismatch between the vaccine composition and the predominant circulating strains.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Pediatrics

Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study

Anita Uka et al.

Summary: This study confirms that COVID-19 is mostly mild in children, with fever, rash, and comorbidities associated with higher admission rates. Continuous observation is crucial for further understanding pediatric COVID-19, guiding therapy, and evaluating the necessity of vaccination in children.

EUROPEAN JOURNAL OF PEDIATRICS (2022)

Add to Collection

Article Immunology

Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Old-New Vaccine Surveillance Network 2016-2017 and 2017-2018

Sara S. Kim et al.

Summary: Influenza vaccine had effectiveness of 71%, 46%, and 45% against A(H1N1)pdm09, A(H3N2), and B viruses, respectively in children during the 2016-2017 and 2017-2018 seasons. Vaccination offered substantial protection against severe influenza outcomes requiring hospitalization or emergency department visits among children during high-severity seasons with concerns for vaccine mismatch.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Covid-19 Vaccine Effectiveness in New York State

Eli S. Rosenberg et al.

Summary: The effectiveness of the BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines in New York State from May to August 2021 was assessed. Initial protection was high, but there was a modest decline in effectiveness after the surge of the delta variant, especially among recipients aged 65 and older. However, protection against hospitalization remained high.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

E. B. Walter et al.

Summary: A regimen of two 10-mu g doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children aged 5 to 11 years.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Jill M. Ferdinands et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Medicine, General & Internal

Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance

Katherine E. Fleming-Dutra et al.

Summary: The efficacy of two doses of BNT162b2 COVID-19 vaccine against symptomatic infection was modest and decreased rapidly in children and adolescents. However, the effectiveness increased after a booster dose in adolescents.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Medicine, General & Internal

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

A. M. Price et al.

Summary: In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness. Vaccine effectiveness against hospitalization was 68% among children 5 to 11 years of age.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

Kristie E.N. Clarke et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

Ashley L. Fowlkes et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Nicola P. Klein et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Letter Medicine, General & Internal

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

Nicole P. Hachmann et al.

Summary: A small study found that omicron subvariants BA.2.12.1, BA.4, and BA.5 of SARS-CoV-2 were more likely to evade neutralizing antibodies induced by both vaccination and previous infection compared to the prior omicron subvariants BA.1 and BA.2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age

Sharon H. X. Tan et al.

Summary: This study found that the BNT162b2 vaccine reduced the risks of SARS-CoV-2 infection and Covid-19-related hospitalization among children 5 to 11 years of age during a period when the omicron variant was predominant.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

Ruth Link-Gelles et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

Sara Y. Tartof et al.

Summary: This study evaluated the vaccine effectiveness (VE) and durability associated with 2 doses of BNT162b2 against Delta- and Omicron-related emergency department (ED) and urgent care (UC) encounters among adolescents aged 12 to 17 years. The findings showed that 2 doses of the BNT162b2 vaccine provided high levels of protection against ED and UC encounters related to the Delta and Omicron variants in the first few months, but effectiveness waned over time, especially against Omicron. A third dose of BNT162b2 was associated with improved protection against Omicron, emphasizing the importance of boosters for adolescents in this age group.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Immunology

Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020

Mark W. Tenforde et al.

Summary: This study investigated the vaccine effectiveness against emerging influenza viruses during the 2019-2020 season in the United States. The results showed that the vaccine provided good protection against B/Victoria viruses, but lower effectiveness against A(H1N1)pdm09 viruses, mainly due to vaccine mismatch caused by antigenic drift. The study observed the impact of antigenic drift on vaccine protection, with significant protection still observed even in drifted years.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Immunology

Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis

Mejbah Uddin Bhuiyan et al.

Summary: This study reviewed the epidemiological and clinical characteristics of COVID-19 infection in children under five years old, revealing that approximately half of the cases were infants, about half of the cases were asymptomatic, and a small portion required hospitalization. Ongoing surveillance is needed to better understand the transmission and clinical presentation of COVID-19 in young children.

VACCINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020

Kathleen Dooling et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Immunology

Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B/Victoria Viruses, 2019-2020

Angela P. Campbell et al.

Summary: The study demonstrated that during the 2019-2020 influenza season, influenza vaccination offered significant protection against influenza-associated hospitalizations and emergency department visits among children in the United States, including against the emerging B/Victoria virus subclade.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021

Kate R. Woodworth et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021

Megan Wallace et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Medicine, General & Internal

Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19

Leigh Ellyn Preston et al.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

M. G. Thompson et al.

Summary: A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health